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Abstract
Objective: Although fatigue is one of the most problematic symptoms for people with systemic sclerosis, little is known
about how fatigue impacts daily life over time. Such information is important when developing fatigue management
interventions. This study was conducted to examine (1) if fatigue severity predicted outcomes of worse functioning
(social participation, physical function), and quality of life and (2) if level of self-efficacy moderated significant relationships
between fatigue and these outcomes.
Methods: Data were utilized from a clinical trial in which an online self-management intervention was tested (N = 267).
Fatigue, social participation, and physical function were assessed by PROMIS measures. Quality of life was assessed
by the EuroQol 5-domain instrument. Linear regressions were performed to examine how baseline fatigue related
to functioning and quality of life outcomes 16 weeks later controlling for relevant covariates. PROMIS measures were
used to measure self-efficacy in managing symptoms, daily activities, medications and treatments, emotions, and social
interactions.
Results: Fatigue at baseline significantly predicted social participation 16 weeks later, but did not predict physical
functioning or quality of life. Self-efficacy variables did not moderate the association between fatigue and social
participation.
Conclusion: Fatigue severity predicted decreased social participation in people with systemic sclerosis. Interventions
targeting fatigue should include support to maintain participation of social roles and activities. The level of reported
self-efficacy did not vary the strength of the association between fatigue and decline in social participation indicating that
there may be other targets to treat fatigue intervention beyond self-management.
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Introduction

Methods

Systemic sclerosis (SSc) is a rare autoimmune disease
characterized by skin thickening in the extremities that
may progress to internal organs and impair vascular, pulmonary, and gastrointestinal functioning.1,2 Although disease presentation and progression are heterogeneous, most
individuals with SSc have high symptom burden, and
fatigue is ranked as one of the most problematic symptoms.3–7 Individuals with SSc have described fatigue’s
debilitating effects affecting the ability to perform daily
living tasks,6,8 work,9–11 and parent.12–14 When assessed
over time, fatigue was found to be high and relatively stable over 2- to 4-year periods, suggesting a missed opportunity to help individuals with SSc manage fatigue.15,16
Despite the unmet need, there are currently no established
fatigue management interventions for this population.
The ability to create relevant fatigue management interventions is limited by the lack of longitudinal studies on
fatigue’s effect on functioning and quality of life. Such
information will provide guidance on which elements
should be integrated into new interventions. An earlier
cross-sectional study showed that fatigue had a strong negative association with social participation, but not healthrelated quality of life or physical function.17 However, one
longitudinal study found that worsening fatigue was associated with worsening hand function.18
There is also limited information on key moderators of
the relationship between fatigue and outcomes over time
which would not only help indicate who may be in most
need of intervention, but may also provide support for
which factors may be protective against fatigue’s impact
on outcomes. Self-efficacy, confidence in ability to manage symptoms (such as pain) has been identified as a
potential moderator of a person’s response to chronic pain
interventions.19,20 Because improvement in self-efficacy is
a mechanism that leads to improved function,21 people
with low self-efficacy may be at risk for having fatigue
that is influential on outcomes over time.
To help plan a fatigue management intervention, this
study aimed to (1) examine if baseline fatigue predicted
social participation, physical function, and health-related
quality of life from baseline to 16 weeks and (2) determine if
baseline self-efficacy moderated any significant associations
between fatigue and these outcomes. We utilized data from a
previous randomized clinical trial (RCT) that compared an
online self-management program versus a control arm to
increase self-efficacy for managing symptoms.22 In that
RCT, there were no statistically significant differences
between groups at 16 weeks and no significant mean changes
within groups on self-efficacy or symptom measures over
time. We hypothesized that fatigue at baseline would predict
decreased social participation, reduced physical function,
and worse health-related quality of life at 16 weeks. We also
hypothesized that greater self-efficacy would diminish the
association between fatigue and decline in these outcomes.

Recruitment was undertaken at two universities, on websites, and social media.22 Inclusion criteria were being a
US resident, SSc diagnosis, age ⩾ 18 years, basic computer
literacy, access to Internet and email, and English speaking. After informed consent was obtained, participants
were sent an online survey to complete baseline assessments. Participants were then randomized into the 16-week
intervention or to the control arm; randomization was
stratified by baseline depressive symptom scores to ensure
adequate distribution in each arm. Participants in the intervention were provided log-in information to the secure
intervention website and provided a new learning module
weekly. Participants in the control arm received a scleroderma book written for patients with SSc. Both groups
were contacted by the study team every 4 weeks and provided gift card incentives throughout the study. Postintervention, all participants were sent the same survey
battery as provided at baseline. The study was approved by
institutional human subjects review boards at University
of New Mexico, University of Michigan, and Medical
University of South Carolina.

Measures
Fatigue was measured by the fatigue subscale of Patient
Reported Outcomes Measurement Information System
29 version 2.0 (PROMIS v.2) at baseline and 16 weeks.23
The PROMIS 29 v.2 instrument has been in validated in
an SSc sample.24 Scores were converted to a T-score metric where a mean of 50 and standard deviation (SD) of 10
represents the US population; higher scores indicate
worse fatigue. Outcomes of social participation, physical
function, and quality of life were assessed at baseline and
16 weeks. PROMIS 29 v.2 was also used to measure
social participation (Ability to Participate in Social Roles
and Activities) and physical function. Scores were converted to T scores; higher scores indicate better ability/
function. Health-related quality of life was measured by
the EuroQol 5-domain instrument (EQ-5D-5L), a commonly used instrument in samples with chronic conditions.25 Participants rate their health state in the areas of
mobility, self-care, activity, pain, and anxiety on a scale
of no problems, slight problems, moderate problems,
severe problems, and extreme problems. Responses are
transformed to a health utility metric using a specific
algorithm. The possible range of scores are from 0 to 1.0
(full/optimal health).26
Five domains of self-efficacy were assessed as moderators from the PROMIS Self-Efficacy for Managing
Chronic Conditions assessment27: self-efficacy for managing symptoms, performing daily activities, managing medications and treatments, managing emotions, and managing
social interactions. Scores were transformed to a T metric
with higher scores indicating greater self-efficacy.
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Table 1. Baseline and 16-Week Symptoms, Function, and Quality of Life Variables.
Measures

Baseline (N = 267)

16 weeksa

Fatigue
Pain interference
Pain intensity (0–10 NRS)
Depressive symptoms
Self-efficacy for managing social interactionsb
Self-efficacy for managing daily activitiesb
Self-efficacy for managing medications/treatmentsb
Self-efficacy for managing symptomsb
Self-efficacy for managing emotionsb
Social Participation
Physical Function
Quality of Life (EQ-5D-5L)

58.7 (10.4)
58.0 (9.3)
4.2 (2.2)
51.3 (9.8)
45.1 (39.4–52.9)
43.6 (40.1–48)
50.4 (42.7–55.5)
46.8 (41.9–53.1)
46.4 (41.6–51.3)
45.0 (8.2)
40.4 (7.1)
0.78 (0.08)

58.7 (10.8)
57.2 (9.4)
4.1 (2.3)
51.2 (9.6)
46.7 (40–59.8)
43.4 (39.7–48.8)
50.9 (42–60.6)
46.9 (42.3–53.6)
46.7 (40.4–52)
46.3 (9.2)
40.9 (7.8)
0.71 (0.17)

The PROMIS 29 v.2 was used which comprised scales of Fatigue, Pain Interference, Pain Intensity, Depressive symptoms, Self-efficacy variables, Ability
to Participate in Social Roles (Social Participation), and Physical Function. NRS: numerical rating scale; EQ-5D-5L: EuroQol 5-domain instrument.
a
In all, 92% follow-up data (N = 246) for fatigue, pain interference, pain intensity, depressive symptoms, self-efficacy for managing emotions, and
social participation; 93% follow-up data (N = 247) for Self-efficacy for managing social interactions, Self-efficacy for managing daily activities,
Self-efficacy for managing medications/treatments, Self-efficacy for managing symptoms, and Quality of Life EQ-5D-5L.
b
Median (interquartile range).

Demographic, clinical characteristics, and other
covariates
Demographic information included age, race, ethnicity,
sex, education level, marital status, and employment status. Clinical characteristics included scleroderma subtype
(limited/CREST/sine, diffuse, or overlap) and disease
duration (based on year diagnosed). Participants rated their
overall health as excellent, very good, good, fair, or poor.
Symptom covariates in the multivariable models included
pain interference and depressive symptoms as assessed
from the PROMIS 29 v.2. Higher scores indicated worse
symptoms.

Data analysis
Baseline characteristics were described by frequency and
proportion for categorical data, mean and SD for normally
distributed continuous data, and median and interquartile
range for non-normally distributed continuous data. Linear
regression was used to assess the association between
fatigue at baseline and outcomes 16 weeks later in separate
analyses for social participation, physical function, and
health-related quality of life. Models were adjusted for
baseline level of the outcome and covariates: age, gender,
ethnicity, scleroderma type, years since diagnosis, pain
interference and depressive symptom scores at baseline,
treatment group, and, for social participation and quality of
life outcomes, baseline level of physical function. Selfefficacy domains assessed at baseline were then investigated as possible moderators of the association between
fatigue and the outcomes by inclusion of interaction terms
in models.

Results
The sample of 267 participants consisted of 91%
women; the mean age was 53.7 (range 20–83 years).22
Seventeen percent of the sample was non-White and
64% was married. The sample had a mean of 16 years of
education, with 74% who reported having a degree or
equivalent professional qualification. With regard to
work status, 26% were on disability or sick leave.
Subtypes of SSc most frequently reported were limited
or sine (45%), followed by diffuse (43%); and SSc overlap with another rheumatic disease (12%). The median
reported time since diagnosis was 9 years (interquartile
range of 5–16 years). Self-rated health was reported to
be fair or poor for 44% of the sample.
Values for symptom, functioning, and quality of life
measures are shown in Table 1. As this was a non-significant trial, values from baseline and 16-week outcome periods are shown for the entire sample; specific values by
study arm have been reported elsewhere.22 Symptoms
remained relatively stable between baseline and 16 weeks.
Fatigue and pain interference were rated as most severe of
the symptoms; mean T scores were .87 and .80 SD above
the US population. Depressive symptoms and the majority
of self-efficacy measures were all within .5 SDs of the normative sample mean, except for self-efficacy to manage
daily activities which was lower than the normative sample by .64 SD. Of outcomes of social participation and
physical functioning, physical functioning was lower by
comparison. Reported physical function was almost 1 SD
below a normative population whereas social participation
was within .5 SD. Health-related quality of life health utility score from the EQ-5D-5L of .78 was also rated below
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Table 2. Baseline Fatigue as a Predictor of Social Participation, Physical Function, and Quality of Life at 16 Weeks.
Baseline variables

Social participation
(n = 245)
B

Fatigue
−0.13
Age
−0.003
Female
−0.98
Minority
−0.43
SSc typea
Diffuse
0.54
Overlap
−0.21
Years since dx
−0.03
Pain interference
0.01
Depressive symptoms −0.02
Treatment (Intervention armb)
Control
1.76
Social participation
0.65
Physical function
0.19
Quality of life
–

95% CI

Physical function
(n = 245)
p

B

95% CI

Quality of life
(n = 244)
p

B

95% CI

p

[−0.24, −0.02]
[−0.07, 0.06]
[−3.54, 1.58]
[−2.40, 1.53]

0.02
0.92
0.45
0.67

−0.04
−0.03
−0.38
0.03

[−0.12, 0.05]
[−0.08, 0.03]
[−2.54, 1.79]
[−1.63, 1.70]

0.39
0.36
0.73
0.97

−0.002
0.002
0.006
0.05

[−0.004, 0.0006]
[0.0005, 0.004]
[−0.05, 0.06]
[0.002, 0.09]

0.16
0.008
0.84
0.04

[−1.02, 2.09]
[−2.65, 2.24]
[−0.12, 0.05]
[−0.10, 0.13]
[−0.11, 0.07]

0.50
0.87
0.42
0.80
0.65

−0.34
−1.68
0.004
−0.02
−0.02

[−1.66, 0.98]
[−3.76, 0.40]
[−0.07, 0.08]
[−0.11, 0.08]
[−0.10, 0.05]

0.61
0.11
0.91
0.74
0.57

0.007
−0.005
−0.001
−0.001
−0.002

[−0.03, 0.04]
[−0.06, 0.05]
[−0.003, 0.0008]
[−0.004, 0.002]
[−0.004, 0.0002]

0.70
0.86
0.26
0.46
0.08

[0.33, 3.19]
[0.50, 0.80]
[0.04, 0.33]

0.02
<0.001
0.01

0.54

[−0.67, 1.75]

0.38

0.01

[−0.02, 0.04]

0.50

0.003
0.83

[−0.0001, 0.006]
[0.52, 1.15]

–

–
0.82

–

[0.71, 0.93]

< 0.001

0.06
<0.001

CI: confidence interval; SSc: systemic sclerosis; dx: diagnosis.
a
Limited SSc is the reference group.
b
Intervention arm is the reference group.

the population norms of adults in other countries which
was approximately .91–.92,28,29 but slightly higher than
what was seen in other studies of SSc (median of .69 and
.75).30,31
Results from the three linear regression models in
which baseline fatigue was examined as a predictor of
social participation, physical function, and health-related
quality of life at 16 weeks, respectively, are presented in
Table 2. Of these models, baseline fatigue only predicted
social participation. Higher fatigue severity predicted
lower social participation 16 weeks later, with every
1-point increase in fatigue corresponding to a .13 decrease
in social participation. Greater baseline social participation and physical function contributed to higher social participation at 16 weeks. Participants in the control arm had
increased participation compared to the treatment group at
16 weeks, although this increase was minimal (less than a
2-point difference). Moderator analyses were performed in
which self-efficacy variables were tested in the model in
which social participation was the outcome. Self-efficacy
variables did not moderate the association between fatigue
and social participation.

Discussion
In this post hoc analysis, we examined if and how baseline
fatigue severity predicted measures of functioning (social
participation and physical function) and health-related
quality of life 16 weeks later. In SSc, there have been few
longitudinal studies in which fatigue and these outcomes
are examined longitudinally,16,10 and none have measured

social participation specifically. We found that baseline
fatigue severity only predicted worse social participation,
but had no significant impact on physical function and
health-related quality of life. The effect of fatigue on social
participation but not physical function may be reflecting
how people adapt to living with SSc. In a framework of
disability, it has been proposed that daily life activities are
obligatory, such as dressing or meal preparation; committed, such as work or caring for one’s children; or discretionary, such as social activities, exercise, or hobbies.32
Studies in samples of people with rheumatic conditions
other than SSc have shown that activities are intentionally
limited or restricted, with discretionary activities being
reduced to preserve time and energy for more obligatory
activities.33–35 This pattern has also been shown in SSc in
which people reported lower participation in social activities compared to domestic and household maintenance
activities.36 It may be that people with SSc and fatigue are
reducing social participation to optimize basic physical
functioning necessary to their everyday living. In this
study, social participation was measured in general categories of activities including work, leisure, and activities
with family and friends by the PROMIS 29 without reflecting nuances of this framework. Despite this general measurement of social participation, the association of fatigue
and social participation found in this study is concordant
with SSc literature. There is an association between fatigue
and work disability9–11 and marked declines in ability to
work over time.10 Furthermore, qualitative studies involving people with SSc have depicted how fatigue interferes
with social and leisure activities and the ability to carry out
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life roles.8,12–14 This study established a longitudinal association between fatigue and social participation; however,
further research is needed to examine processes by which
people with SSc restrict their social participation and how
fatigue influences the process.
Fatigue was not a significant predictor of health-related
quality of life in SSc. Fatigue and health-related quality of
life in SSc are associated in cross-sectional studies,30,31 but
it appears that factors other than fatigue may be more consequential. In one study, the association between fatigue
and health-related quality of life was diminished when disability was added in the multivariate model.37 In a crosssectional analysis using baseline data from this study, we
examined relative influence of fatigue, pain interference,
and depression on health-related quality of life using hierarchical models. Fatigue only added 1% additional variance in health-related quality of life after pain interference
and depression were added, which combined explained
53% of the variance.17
This study provides support for assessing fatigue in
clinical practice as it may have profound effects on the
daily lives of individuals with SSc affecting their participation in activities, routines, and life roles. Fatigue in
rheumatic diseases is under-studied6,38 and perceived by
individuals with SSc as under-addressed in clinical care,39
but one of the challenges to intervening on fatigue is that it
is multifactorial in nature. Thombs et al. conceptualized
fatigue in SSc as a combination of etiological factors (such
as inflammatory cytokines), disease-specific manifestations (such as connective tissue changes), comorbidities,
psychosocial factors, lifestyle habits, and contributors
such as pain and sleep issues.38 Basta developed a conceptual model with similar domains but also highlights the
potential importance of work disability and sociodemographic contributors.4 Longitudinal studies in SSc in which
predictors of fatigue severity are examined support this
multifactorial model. For instance, in a study where people
were followed for a mean of 3.8 years, predictors of fatigue
severity included baseline measures of ineffective coping
skills (as reported on an illness behavior questionnaire),
pain, and gastrointestinal symptom severity.15 Furthermore,
decreased lung function was a predictor of change in
fatigue during that period. Another study in which 215
patients with SSc were followed over a 3-year period again
found that symptoms of lung involvement and coping
skills (in this case, less acceptance of one’s condition)
were independent predictors of higher fatigue, in addition
to being female.16 Addressing potentially modifiable factors would require a multi-modal approach and likely need
to utilize a variety of care providers in fatigue management, including physicians, occupational and physical
therapists, and psychologists. A better characterization of
fatigue and its impact in future studies is warranted to
identify optimal intervention strategies to target specific
aspects of fatigue.
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One potential clinical implication is the support for
interventions targeting the relationship between fatigue
and social participation. Because fatigue seems to affect
participation in social roles and activities, occupational
therapists are particularly well-suited to work with these
individuals as their main practice domain involves identification, resolution of, or adaptation to problems with participation in daily life roles and activities.40 Despite this
potential avenue for intervention, a recent review showed
that rehabilitation services including occupational therapy
and physical therapy are not well-utilized among people
with SSc.41 Thus, more education to providers regarding
these services may be needed to promote referrals.
Interestingly, in this study, level of self-efficacy for
managing different aspects of chronic disease did not moderate the association between baseline fatigue and decline
in social participation. In essence, a person’s higher selfefficacy at baseline was not protective against fatigue’s
effect on social participation. This finding may have potentially important implications for development of fatigue
management interventions. While increasing self-efficacy
can be useful in many aspects of disease management, a
fatigue intervention that focuses only on increasing selfefficacy in managing fatigue may not have the desired outcome of reducing effects on social participation.
Our study has strengths. First, it utilized a well-conducted RCT that captured data in subjects with SSc over a
period of 16 weeks. Second, we were able to assess the
prospective relationship between baseline fatigue and outcome measures of interest due to longitudinal nature of the
data.
Limitations of this study include utilization of self-report
of participants who voluntarily participated in an RCT on an
online self-management program. In addition, findings may
be generalized only to people who use computers and have
Internet access and who were not newly diagnosed, as the
median disease duration was 9 years. The report of disease
characterization such as subtype and duration of disease
could not be verified by medical record. A 16-week duration
to look at longitudinal effects is relatively short, and a longer
follow-up period may provide more insight on the nature
and persistence of effects (and may explain a lack of effect
on physical functioning and health-related quality of life).
The longitudinal data were gathered from people in an RCT,
although there were no meaningful changes in the intervention and control groups. Future studies could provide a more
nuanced measurement of social participation and should
consider mixed-methods approaches to understand how
much the fatigue–social participation association has a perceived impact on individual’s lives. Finally, our study was
limited by having only two assessment periods involving
recall-based measures. A more intensive measurement protocol using ecological momentary assessment that would
ascertain trajectories of fatigue and social participation over
time would better characterize temporal patterns.
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Conclusion
Fatigue severity predicted decreased social participation in
people with SSc. The level of reported self-efficacy did not
vary the strength of the association between fatigue and
decline in social participation. Interventions targeting
fatigue should include support to maintain participation of
social roles and activities. A better understanding of the
outcomes that fatigue most impacts can enable the design
of an optimal fatigue management intervention that may
include medical and behavioral-based targets. More
research will be needed to characterize fatigue and its
impact on individuals with SSc to inform this intervention
development.
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